Eli Lilly has struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash. Eli Lilly on Monday said Orna, which is dedicated to engineering immune ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min How Holly Springs went from ...

Feb 4 (Reuters) - Biotech firm Bio-Techne (TECH.O), opens new tab beat analysts' estimates for second-quarter revenue and profit on Wednesday, helped by robust demand for its products used in drug ...

Stem cell therapy biotech PrimeGen US is taking the less-traveled special purpose acquisition company (SPAC) route to the public markets. The California biotech, which is working on preclinical stem ...

Nearly 100 biotechs went public amid the industry’s IPO frenzy in 2021, driven by an influx of pandemic-driven investments. But many of those companies have little to show investors. Four years ago, ...